ESTRO 2024 - Abstract Book

S2010

Clinical - Mixed sites, palliation

ESTRO 2024

Associations between PSQI scale and age and origin were not statistically significant. There was a significant correlation between sleep disorders and the PSQI score and the presence of pain (p=0.004) and anxiety (p=0.001).

Conclusion:

Sleep and mental health disorders are common among cancer patients undergoing radiotherapy wich may affect their quality of life. Adequate management of these disorders is essential, and must represent an integral part of treatment

Keywords: depression, anxiety, radiotherapy

3127

Digital Poster

MR-guided SABR re-irradiation: patterns of care and identifying potential isotoxic dose escalation

Ben George 1 , Daniel Murray 1,2 , Elena Moreno-Olmedo 3 , Philip Camilleri 3 , Veni Ezhil 3 , James Good 3

1 GenesisCare UK, Medical Physics, Oxford, United Kingdom. 2 University of Oxford, Department of Oncology, Oxford, United Kingdom. 3 GenesisCare UK, Oncology, Oxford, United Kingdom

Purpose/Objective:

The use of re-irradiation to achieve local control in patients with few other options is increasing [1]. However, optimal doses to achieve ablative aim are challenging, due to related normal tissue toxicities from cumulative doses and treatment failure because radioresistant tumour phenotypes. MR-guided radiotherapy (MRgRT) provides several advantages that allow extreme fractionation delivery to moving targets while sparing surrounding critical structures: daily plan adaption; real-time imaging; tracking and gating [2]. These capabilities allow opportunities to explore the feasibility of isotoxic dose escalation in the setting of re-irradiation which may improve tumour control with acceptable toxicity [3, 4]. This single-institution retrospective study explores the clinical and dosimetric characteristics of a cohort of patients treated with daily-adapted MRgRT SABR re-irradiation to abdominal and thoracic targets, with the further aim of identifying cases which could have been considered for isotoxic dose escalation.

Material/Methods:

Patients treated between December 2019 and October 2023 with daily-adapted MRgRT SABR re-irradiation to abdominal or thoracic targets were considered. Re-irradiation type was classified in accordance with ESTRO consensus [1]. Demographics, clinical indications, prescription information, treatment planning and dosimetric data were evaluated for all patients.

Cases considered suitable for possible dose escalation met both the following criteria: 1. Over 90% of the PTV receiving the original prescription dose; 2. Dose prescription ≤40Gy in 3 - 8#. These criteria indicate that further a